RECRUITING

ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia

Conditions

Beta-Thalassemia Thalassemia Beta Thalassemia gene therapy beta globin gene

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The main goal of this study is to find out if the blood disorder called transfusion-dependent beta thalassemia can be safely treated by modifying blood stem cells. This is done by collecting blood stem cells from the subject, modifying those cells, adding a healthy beta globin gene, and then giving them back to the subject. It is hoped that these modified cells will decrease the need for blood transfusions. The gene modified blood stem cells are called CHOP-ALS20 ("study drug"). This experimental gene therapy has not been tried on human beings before and is not FDA approved.

Official Title

Phase 1/2 Study Evaluating the Safety and Efficacy of Gene Therapy Employing Lentiviral Vector ALS20-transduced Hematopoietic Progenitor Cells in Subjects With Transfusion-dependent-thalassemia

Quick Facts

Study Start:2025-01-01

Study Completion:2027-12-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06364774

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 35 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
1. Age 18 to 35 years at the time of consent 2. Diagnosis of transfusion dependent beta thalassemia (β0 β0, β+β0, β+β+, βEβ0, βEβ+,β0 or β+ /βA + alpha triplication(s)). Transfusion-dependent is defined as a history of receiving at least 120 mL/kg/year packed red blood cells or at least 8 transfusions per year in the past two years. The first 2 subjects enrolled must have a non- β0 β0 genotype. 3. Genetic confirmation of α and β thalassemia diagnosis (β0β0, β+β0, β+β+, βEβ0, Eβ+ dominant β-thalassemia) by a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory is required. 4. Clinically stable, Karnofsky score 70, and eligible to undergo Hematopoietic Stem Cell Transplantation (HSCT). 5. Female subjects of childbearing potential must agree to use acceptable method(s) of contraception from consent through at least 6 months after CHOP-ALS20 infusion 6. Male subjects of reproductive capacity must agree to use effective contraception from start of mobilization through at least 6 months after CHOP-ALS20 infusion	1. Prior receipt of HSCT or gene therapy 2. An available Human Leukocyte Antigen (HLA)-matched family donor 3. More than one alpha globin gene deletions/mutations. 4. Any prior or current malignancy (excluding adequately treated basal or squamous cell carcinoma of the skin) 5. Known cancer predisposition syndrome 6. Positive for HIV-1, HIV-2, Human T Cell Lymphotropic Virus-1,2 (HTLV-1, HTLV-2) or active hepatitis B or active hepatitis C infection 7. Clinically significant active bacterial, viral (including COVID-19 and influenza), fungal, or parasitic infection (temporary exclusion) 8. Clinically significant bleeding disorder 9. Evidence of cardiac dysfunction (left ventricular ejection fraction \<50% or shortening fraction \<27%) or clinically significant arrhythmia 10. Evidence of advanced liver disease (ALT \>5x the upper limit of normal (ULN), prothrombin time \>1.5 x ULN, direct bilirubin \> 3x ULN) not attributable to iron chelation therapy, or evidence of bridging fibrosis on liver biopsy or fibrosis stage of F3 or higher by magnetic resonance elastography (MRE) if obtained as part of clinical care 11. Liver R2 or R2 MRI or liver biopsy with liver iron concentration 15 mg/g dw (temporary exclusion) 12. Diffusion capacity of carbon monoxide (DLco) \<50% of predicted (corrected for Hb) 13. Pulse oximetry in room air \<92% 14. Evidence of renal dysfunction (creatinine \>1.5x ULN or Glomerular Filtration Rate (GFR) \<70 ml/min/1.73 m2 based on cystatin C/creatinine equation) 15. Cardiac T2 MRI \< 10 ms 16. Platelet count \<100,000/mcL or absolute neutrophil count \<1000/mcL except if attributed to benign ethnic neutropenia 17. Unable to receive red cell transfusion (significant allo/auto immunization) 18. Uncontrolled systemic hypertension 19. Uncontrolled seizure disorder 20. Diagnosis of a significant psychiatric disorder that could seriously impede the ability to participate in the study 21. Immediate family member with a known or suspected Familial Cancer Syndrome 22. Contraindication to anesthesia 23. For female subjects, pregnancy or breastfeeding 24. Participation in another clinical trial of an investigational drug within 30 days or 5 drug half-lives, whichever is longer, of screening (temporary exclusion) 25. Any other condition that would render the subject ineligible for mobilization/apheresis and/or HSCT as determined by the investigator

Inclusion Criteria

Exclusion Criteria

1. Age 18 to 35 years at the time of consent
2. Diagnosis of transfusion dependent beta thalassemia (β0 β0, β+β0, β+β+, βEβ0, βEβ+,β0 or β+ /βA + alpha triplication(s)). Transfusion-dependent is defined as a history of receiving at least 120 mL/kg/year packed red blood cells or at least 8 transfusions per year in the past two years. The first 2 subjects enrolled must have a non- β0 β0 genotype.
3. Genetic confirmation of α and β thalassemia diagnosis (β0β0, β+β0, β+β+, βEβ0, Eβ+ dominant β-thalassemia) by a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory is required.
4. Clinically stable, Karnofsky score 70, and eligible to undergo Hematopoietic Stem Cell Transplantation (HSCT).
5. Female subjects of childbearing potential must agree to use acceptable method(s) of contraception from consent through at least 6 months after CHOP-ALS20 infusion
6. Male subjects of reproductive capacity must agree to use effective contraception from start of mobilization through at least 6 months after CHOP-ALS20 infusion

1. Prior receipt of HSCT or gene therapy
2. An available Human Leukocyte Antigen (HLA)-matched family donor
3. More than one alpha globin gene deletions/mutations.
4. Any prior or current malignancy (excluding adequately treated basal or squamous cell carcinoma of the skin)
5. Known cancer predisposition syndrome
6. Positive for HIV-1, HIV-2, Human T Cell Lymphotropic Virus-1,2 (HTLV-1, HTLV-2) or active hepatitis B or active hepatitis C infection
7. Clinically significant active bacterial, viral (including COVID-19 and influenza), fungal, or parasitic infection (temporary exclusion)
8. Clinically significant bleeding disorder
9. Evidence of cardiac dysfunction (left ventricular ejection fraction \<50% or shortening fraction \<27%) or clinically significant arrhythmia
10. Evidence of advanced liver disease (ALT \>5x the upper limit of normal (ULN), prothrombin time \>1.5 x ULN, direct bilirubin \> 3x ULN) not attributable to iron chelation therapy, or evidence of bridging fibrosis on liver biopsy or fibrosis stage of F3 or higher by magnetic resonance elastography (MRE) if obtained as part of clinical care
11. Liver R2 or R2 MRI or liver biopsy with liver iron concentration 15 mg/g dw (temporary exclusion)
12. Diffusion capacity of carbon monoxide (DLco) \<50% of predicted (corrected for Hb)
13. Pulse oximetry in room air \<92%
14. Evidence of renal dysfunction (creatinine \>1.5x ULN or Glomerular Filtration Rate (GFR) \<70 ml/min/1.73 m2 based on cystatin C/creatinine equation)
15. Cardiac T2 MRI \< 10 ms
16. Platelet count \<100,000/mcL or absolute neutrophil count \<1000/mcL except if attributed to benign ethnic neutropenia
17. Unable to receive red cell transfusion (significant allo/auto immunization)
18. Uncontrolled systemic hypertension
19. Uncontrolled seizure disorder
20. Diagnosis of a significant psychiatric disorder that could seriously impede the ability to participate in the study
21. Immediate family member with a known or suspected Familial Cancer Syndrome
22. Contraindication to anesthesia
23. For female subjects, pregnancy or breastfeeding
24. Participation in another clinical trial of an investigational drug within 30 days or 5 drug half-lives, whichever is longer, of screening (temporary exclusion)
25. Any other condition that would render the subject ineligible for mobilization/apheresis and/or HSCT as determined by the investigator

Contacts and Locations

Study Contact

Janet Kwiatkowski, MD

CONTACT

215-590-5286

kwiatkowski@chop.edu

Jaladhikumar Patel

CONTACT

267-426-5602

patelj23@chop.edu

Principal Investigator

Janet Kwiatkowski, MD

PRINCIPAL_INVESTIGATOR

Children's Hospital of Philadelphia

Study Locations (Sites)

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104

United States

Collaborators and Investigators

Sponsor: Children's Hospital of Philadelphia

Janet Kwiatkowski, MD, PRINCIPAL_INVESTIGATOR, Children's Hospital of Philadelphia

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-01

Study Completion Date2027-12-31

Study Record Updates

Study Start Date2025-01-01

Study Completion Date2027-12-31

Terms related to this study

Keywords Provided by Researchers

Thalassemia
Beta Thalassemia
gene therapy
beta globin gene

Additional Relevant MeSH Terms

Beta-Thalassemia